Phase 1, Randomised, Single-centre, Observer-blind Clinical Trial of Safety and Immunogenicity of Nasal-prime and Intramuscular Boost Immunisation With EN41-FPA2 HIV Vaccine in Healthy Female Volunteers.

Trial Profile

Phase 1, Randomised, Single-centre, Observer-blind Clinical Trial of Safety and Immunogenicity of Nasal-prime and Intramuscular Boost Immunisation With EN41-FPA2 HIV Vaccine in Healthy Female Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2014

At a glance

  • Drugs HIV vaccine-PX-Therapeutics (Primary) ; HIV vaccine-PX-Therapeutics (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors PX Therapeutics
  • Most Recent Events

    • 20 May 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Jan 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top